Matches in Nanopublications for { ?s ?p "[PI3K pathway mutations co-occurred with BRAF(V600) mutations in 17% of the tumors and co-occurred with 9% of NRAS mutant tumors, implying cooperativity between these pathways in terms of melanoma progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 11 of
11
with 100 items per page.
- NP201035.RAcCXEQUukDZXaIxiZTac1Cw_qx8hHLROky7L7U1cNTDY130_assertion description "[PI3K pathway mutations co-occurred with BRAF(V600) mutations in 17% of the tumors and co-occurred with 9% of NRAS mutant tumors, implying cooperativity between these pathways in terms of melanoma progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP201035.RAcCXEQUukDZXaIxiZTac1Cw_qx8hHLROky7L7U1cNTDY130_provenance.
- assertion description "[PI3K pathway mutations co-occurred with BRAF(V600) mutations in 17% of the tumors and co-occurred with 9% of NRAS mutant tumors, implying cooperativity between these pathways in terms of melanoma progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[PI3K pathway mutations co-occurred with BRAF(V600) mutations in 17% of the tumors and co-occurred with 9% of NRAS mutant tumors, implying cooperativity between these pathways in terms of melanoma progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[PI3K pathway mutations co-occurred with BRAF(V600) mutations in 17% of the tumors and co-occurred with 9% of NRAS mutant tumors, implying cooperativity between these pathways in terms of melanoma progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[PI3K pathway mutations co-occurred with BRAF(V600) mutations in 17% of the tumors and co-occurred with 9% of NRAS mutant tumors, implying cooperativity between these pathways in terms of melanoma progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[PI3K pathway mutations co-occurred with BRAF(V600) mutations in 17% of the tumors and co-occurred with 9% of NRAS mutant tumors, implying cooperativity between these pathways in terms of melanoma progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1007263.RAcrpz1hzm3B6WIN-BWcve6y-Kf4bMYYSUfvu2hHRStRA130_assertion description "[PI3K pathway mutations co-occurred with BRAF(V600) mutations in 17% of the tumors and co-occurred with 9% of NRAS mutant tumors, implying cooperativity between these pathways in terms of melanoma progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1007263.RAcrpz1hzm3B6WIN-BWcve6y-Kf4bMYYSUfvu2hHRStRA130_provenance.
- NP1007255.RAsEfOl9qXfvs1bxtBqvk7yZhQw2zp6Lp7eTAjuuaM6r0130_assertion description "[PI3K pathway mutations co-occurred with BRAF(V600) mutations in 17% of the tumors and co-occurred with 9% of NRAS mutant tumors, implying cooperativity between these pathways in terms of melanoma progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1007255.RAsEfOl9qXfvs1bxtBqvk7yZhQw2zp6Lp7eTAjuuaM6r0130_provenance.
- NP1007256.RAoOjD5PNE-NqRsGCBez0fW-LeMU8xQFT_AT7JVBN60a8130_assertion description "[PI3K pathway mutations co-occurred with BRAF(V600) mutations in 17% of the tumors and co-occurred with 9% of NRAS mutant tumors, implying cooperativity between these pathways in terms of melanoma progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1007256.RAoOjD5PNE-NqRsGCBez0fW-LeMU8xQFT_AT7JVBN60a8130_provenance.
- NP1007260.RAp37_kHlxYy1eyeSeXmi3Tlw33lQKG-Djb5EFJ9CrlmY130_assertion description "[PI3K pathway mutations co-occurred with BRAF(V600) mutations in 17% of the tumors and co-occurred with 9% of NRAS mutant tumors, implying cooperativity between these pathways in terms of melanoma progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1007260.RAp37_kHlxYy1eyeSeXmi3Tlw33lQKG-Djb5EFJ9CrlmY130_provenance.
- NP1007262.RAxowA7TWS8WyFX-9t3QuZKev753iKDOQAa9kuGxGywhk130_assertion description "[PI3K pathway mutations co-occurred with BRAF(V600) mutations in 17% of the tumors and co-occurred with 9% of NRAS mutant tumors, implying cooperativity between these pathways in terms of melanoma progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1007262.RAxowA7TWS8WyFX-9t3QuZKev753iKDOQAa9kuGxGywhk130_provenance.